Internal Medicine / Oncology

The Washington University physicians in the Department of Internal Medicine encompass 14 specialty clinical divisions.

Over 270 physicians in the department of medicine treat patients with a wide range of diseases, disorders and conditions.

Text Size: S M L

Home > Physicians Directory > Internal Medicine / Oncology

Joel Picus, MD

Specialty Areas
Gastrointestinal Oncology
Pancreatic Cancer
Hematology
Genitourinary Oncology
Oncology
Hepatobiliary Pancreatic Cancer
Colon and Rectal Cancer

Areas of Clinical Interest
Diagnosis of tumors, renal cell carcinoma, RCC, pancreatic cancer, pancreas, cholangiocarcinoma, prostate cancer, colon cancer, bladder cancer, rectal carcinoma, immunotherapy, chemotherapy, GI cancer, GU cancer

Major or Recent Publications/Awards

Honors and Awards

Listed in Best Doctors in America 2003-2009, (Best Doctors, Inc.)

Listed in America's Top Doctors, by Castle & Connolly Ltd., 2007

American Cancer Society Physician Training Award, 1989-1991

Karin Grunebaum Cancer Research Foundation Fellow, 1982-1983

Journal Articles

Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winter E and Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 Study, J Clinical Oncology 1999;17:2506-2513

Naughton M, Haug J, DiPersio J and Picus J. A phase II study of dendritic cell mobilization with GM-CSF in conjunction with IL-2 as immunotherapy for renal cell carcinoma (RCC), an Initial Report, Proc Am Soc Clin Onc 1999; 18:1344

Picus J and Schultz M. A phase II trial of docetaxel in patients with hormone refractory prostate cancer (HRPC): Long Term Results. Proc Am Soc Clin Onc 1999; 18:1206

Clark RS, Fracasso P, Picus J. A phase I study of weekly topotecan as a bolus infusion. Proc Am Soc Clin Onc 1999; 18:793

Myerson RJ, Genovesi D, Lockett MA, Birnbaum E, Fleshman J, Fry R, Kodner I, Menteer J, Picus J, Read T, Walz B. Five fractions of preoperative radiotherapy for selected cases of rectal carcinoma: long-term tumor control and tolerance to treatment. Int J Radiation Oncology Biol Phys 1999; 43:537-543

Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer. The Results of CALGB 9182. J Urol 1999; 161(S 4):680

Schultz M, Wei J and Picus J. A phase II trial of doceaxel in patients with hormone refractory prostate cancer. Proc Am Soc Clin Onc 1998; 17:1320

Pennington K, Gordon M, Picus J A phase II trial of liposomal doxorubicin (DOXIL) in the treatment of advanced renal cell cancer: A Hoosier Oncology Group (HOG) Study. Proc Am Soc Clin Onc 1998; 17:1308

Cohn H, Picus J and Vogelzang NJ. Strontium-89 (SR89), Mitoxantrone(M) and Hydrocortisone (H) in Hormone Refractory Prostaet Cancer (HRPC). Proc Am Soc Clin Onc 1998; 17:1265

John W, Picus J, Blanke C, Clark J, Schulman L, Rowinsky E, Thornton D and Loehrer PJ. Activity of MTA (LY 231514) in patients with advanced colorectal cancer—results from a phase II study. Proc Am Soc Clin Onc 1998 17:1067

Picus J, Myerson R, Drebin J, Strasberg S. A phase II trial of continuous infusion (CIVI) 5-FU with 3-D conformal radiation in the adjuvant treatment of pancreatic, ampullary and biliary cancers. Proc Am Soc Clin Onc 1998; 17:1023

For more articles and abstracts, take this off-site link to the National Library of Medicine Pub Med page for Dr. Picus

Joel Picus, MD